



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2021 #40

November 12, 2021

## INSIDE:

WORD IN WASHINGTON .....	3
RESEARCH IN BRIEF .....	4
BRIEFLY NOTED .....	4
November ABC <i>Blood Bulletin</i> Now Available ..	5
Register for the 60 <sup>th</sup> ABC Annual Meeting .....	5
MEMBER NEWS .....	6
GLOBAL NEWS .....	8
COMPANY NEWS .....	9
CALENDAR .....	10
POSITIONS .....	10

## Congress Includes Blood Transport Provision in Infrastructure Bill

On November 6<sup>th</sup>, Congress passed the [Infrastructure Investment and Jobs Act](#). America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and American Red Cross (ARC) have been working together with Congress to ensure the bipartisan, non-controversial provision to allow blood transportation to use HOV lanes was included in this bill.

The bill states that “[t]he public authority may allow blood transport vehicles that are transporting blood between a collection point and a hospital or storage center to use the HOV facility if the public authority establishes requirements for clearly identifying such vehicles.” President Biden has indicated he will sign the bill as soon as the signing ceremony can be scheduled.

ABC, AABB, and ARC sent letters to members of the [House](#) and [Senate](#) in [April](#) requesting “support and leadership to allow vehicles transporting life-saving blood and blood components to access HOV/carpool lanes.” The blood community explained in the letters that “[b]lood center vehicles with access to the HOV lanes will be transporting blood to laboratories for processing or to hospitals to meet patients’ needs. Particularly in times of an ASAP order or STAT order from hospitals, time is of the essence. Having access to HOV lanes will reduce the current transport time between destinations, maximizing the availability of these life-saving therapies.” The letters also described challenges that can be faced in transporting blood products such as “high volume traffic, construction, or possible accidents may clog the roads and surface streets, preventing needed blood and blood components from reaching their destination in a timely manner.” ♦

## San Diego Blood Bank Announces Community Bio, Inc. — a For-profit Spinoff

San Diego Blood Bank (SDBB) [announced](#) on November 5<sup>th</sup> the “formal spinoff” of Community Bio, Inc. The new organization will be a “a cell therapy Contract Development and Manufacturing Organization (CDMO).” The announcement noted that SDBB will “retain a significant equity interest in Community Bio, and the two will maintain a strategic relationship to continue to advance the Blood Bank’s mission of improving the health and wellness of our community.”

Community Bio, Inc. will be led by David Wellis, PhD, as he “transitions” from his role as chief executive officer (CEO) of SDBB. “For the past several years, the San

(continued on page 2)

SDBB Announces Community Bio, Inc. (continued from page 1)

Diego Blood Bank broadened its scope toward ensuring a healthy community beyond blood banking while not drifting from its mission. We’ve supported research and clinical trials for innovative cellular therapies for cancer, for personalized precision medicine, and other medical advancements,” said Dr. Wellis in a news release. “Creating this new, separate company gives both organizations significant opportunities with very low risk. We’re excited for what’s ahead for both the San Diego Blood Bank and Community Bio!”

Also joining Dr. Wellis in transitioning to the Community Bio team are SDBB’s Chief Scientific Officer, Robert Tressler, PhD, and Chief Commercial Officer George Eastwood. “Doug Morton, SDBB’s current Chief Operating Officer/Chief Information Officer, will assume the role of Interim CEO while SDBB’s Board of Directors conducts a search for a new SDBB CEO.”

The news release also stated that “Community Bio will operate out of the San Diego Blood Bank’s Gateway Center headquarters and reimburse the non-profit organization for space, raw materials, and laboratory services...[The new organization secured funding ] from a venture capital firm dedicated to helping life science, medical device, and healthcare companies achieve their growth objectives...[It] will supply cellular products and services, together with process development and manufacturing expertise, to scientists and clinicians working with cell, gene, and immuno-therapies.”

(Source: SDBB [News Release](#), 11/5/21) ♦



The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2021 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

**America’s Blood Centers**

Chief Executive Officer: Kate Fry  
 Chief Medical Officer: Rita Reik  
 Editor: Mack Benton  
 Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to [memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
 America’s Blood Centers  
 1717 K St. NW, Suite 900, Washington, DC 20006  
 Phone: (202) 393-5725  
 Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).



## WORD IN WASHINGTON

President Biden **announced** today that he will nominate **Robert Califf, MD to be the next commissioner of the U.S. Food and Drug Administration (FDA)**. In the announcement President Biden stated, “Dr. Califf is one of the most experienced clinical trialists in the country and has the experience and expertise to lead the [FDA] during a critical time in our nation’s fight to put an end to the coronavirus pandemic. As the FDA considers many consequential decisions around vaccine approvals and more, it is mission critical that we have a steady, independent hand to guide the FDA. I am confident Dr. Califf will ensure that the FDA continues its science and data driven decision-making. Dr. Califf had strong bipartisan support in the Senate in 2016, and I urge the Senate to swiftly confirm Dr. Califf so he can continue the important work being done at this critical moment.” He also thanked current Acting FDA Commissioner Janet Woodcock, MD, “for her leadership over the last year. She has done an incredible job leading the agency during what has been a busy and challenging time, and both she and the FDA career staff have worked hard and followed the science to ensure the American public can trust the decisions being made by the FDA.” Dr. Califf previously served as FDA Commissioner from 2016-17.



(Source: White House [Statement](#), 11/12/21)

**The National Institutes of Health’s (NIH) National Heart, Lung, and Blood Institute’s (NHLBI) Blood Diseases Education Program is **coordinating** the “Blood Health Network”.** The coalition of public and private organizations have an interest in “blood diseases, disorders, and blood safety” and will aim to:

- [h]elp drive outreach efforts to increase awareness of blood diseases and disorders;
- [e]xtend the reach of blood health messages and materials as well as blood safety to people living with blood diseases and disorders, as well as their family members and caregivers; and
- [i]ncrease understanding and awareness of NHLBI blood science research, as well as clinical trials.

(Source: NHLBI [Announcement](#), 8/31/21) ♦

### Upcoming ABC Webinars – Don’t Miss Out!

- **ABC SMT Journal Club Webinar** – Dec. 13<sup>th</sup>. More details coming soon.

### ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



## RESEARCH IN BRIEF

**Comparison of Liquid vs. Thawed Plasma for Massive Transfusion.** A study in *Vox Sanguinis* reviewed the role of liquid plasma (LP) as part of massive transfusion protocols (MTP). The researchers explained that “thaw time for “[thawed plasma] (TP) [is] approximately 25 minutes [and] can delay administration to massively bleeding patients...The TP shelf life of five days [may incur] wastage...[While]LP can be stored at 1–6 degrees Celsius (C) for up to [26 days].” They stated that “[t]he objective of [this] study was to detect if there is any difference in 24-h survival between patients receiving group A LP or TP during MTPs...All eligible adult male and female patients age 18 years and older receiving ( $\leq 6$  h) emergency transfusion as Level 1 activation for MTP were included in the study...[T]he transfusion service utilize[d] group O red blood cell (RBC) units, group A LP, or TP and one unit of single-donor platelet apheresis in a 4:4:1 ratio for the MTP.” The authors noted that “[t]his retrospective study collected data of trauma patients receiving TP from January 2016 to September 2018 and LP from October 2018 to July 2020...The primary outcome [was] 24-h survival between LP and TP transfusions. Secondary outcomes included hospital length of stay (LOS), in-hospital survival and intensive care unit (ICU) stay.” A total of “178 patients received 1,283 of LP, whereas 270 patients received 2,031 units of TP.” The researchers stated that “[t]here were no statistically significant differences in the amounts of transfused [blood components] as part of the MTP between the two groups ( $p=0.436$ )...There was no difference in the 24-h survival between the two groups ( $p=0.553$ )...[P]atients who received LP were 0.778 (95 percent CI 0.705–1.841,  $p = 0.553$ ) times more likely to survive in 24 h compared to those who received TP...The odds for in-hospital survival was 0.414 (95 percent CI 0.334–1.196,  $p = 0.227$ ) and for ICU stay was 0.614 (95 percent CI 0.532–1.692,  $p = 0.466$ ) of the LP compared to TP.” The authors concluded by explaining that “[this] study did not show a difference between the use of LP compared to TP in trauma patients...LP should be considered an alternative to TP in trauma patients requiring immediate plasma resuscitation.”

**Citation:** Fadeyi, E.A., Saha, A.K., Soltani, S., Naal, T., Palmer, R., Bakht, A., *et al.* [A comparison between liquid group A plasma and thawed group A plasma for massive transfusion activation in trauma patients.](#) *Vox Sang.* 2021

*Contributed by Richard Gammon, MD, Medical Director at OneBlood* 💧

## BRIEFLY NOTED

The Centers for Disease Control and Prevention (CDC) is [hosting](#) its next webinar in the Public Health Webinar Series on Blood Disorders entitled “The Heart in Thalassemia.” The webinar will:

- list the risk factors, consequences, and management of iron cardiomyopathy;
- describe the physiological basis for pulmonary hypertension in thalassemia; and
- describe the interaction of thalassemia with the normal cardiovascular aging process.

[Registration](#) is currently open and the webinar is scheduled to take place on November 18<sup>th</sup> at 2 p.m. EST.

(Source CDC [Announcement](#), 10/29/19) 💧



**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### **November ABC Blood Bulletin Now Available**

ABC's Scientific, Medical, and Technical (SMT) Publications Committee has published the November 2021 Issue of the [Blood Bulletin](#), titled "The Return of Whole Blood — A Blast from the Past." The article was written Samantha Ngamsuntikul, MD, Associate Medical Director at South Texas Blood & Tissue Center, a subsidiary of BioBridge Global; Jed Gorlin, MD, MBA, Vice President of Medical and Quality Affairs at Memorial Blood Centers and Nebraska Community Blood Bank, Divisions of Innovative Blood Resources, a division of New York Blood Center; Thomas Watkins, DO, PhD, Chief Medical Officer at MEDIC Regional Blood Center; Nancy Van Buren, MD, Medical Director at Innovative Blood Resources, a division of New York Blood Center; Mark H. Yazer, MD, Professor of Pathology at University of Pittsburgh. The [Blood Bulletin](#) is reviewed and edited by ABC's SMT Publications Committee. ABC publishes the *Blood Bulletin* for use by member blood centers in their educational programs as a value-added service for hospital customers. Please contact [Member Services](#) for trouble accessing the publication.

*\*\*Please note: The MS Word version may not display properly for users with older versions of MS Word. For those individuals, we recommend viewing and using the PDF version of this publication instead.\*\**

(Source: MCN 21-092, 11/9/21) 💧

### **Register for the 60<sup>th</sup> ABC Annual Meeting**

[Register](#) today for the [60<sup>th</sup> ABC Annual Meeting](#) and 25<sup>th</sup> Annual Awards of Excellence. These events will take place March 7<sup>th</sup>-9<sup>th</sup>, 2022 at the Ritz-Carlton (Pentagon City) in Arlington, Va. Please secure your hotel [reservation](#) today. This year's meeting will be in-person while [Advocacy Day](#) will be held virtually the following week given continued visitor restrictions on Capitol Hill. This will allow each blood center to bring together multiple colleagues to connect with their members of Congress and their staff. More information will be provided to ABC members as it becomes available. The ABC Annual Meeting brings together blood center executives and national leaders to discuss advocacy and regulatory updates, the latest in science, medicine, and technical affairs, and hot topics facing the blood community. In addition, ABC is excited to share that the final day of this year's meeting will feature two in-depth training workshops focused on building tangible advocacy skills that can immediately benefit your center. The preliminary program-at-a-glance is [available](#). Please contact [ABC Member Services](#) with questions. 💧

### **What We're Reading**

- [Health Care CFOs Expand Investment Plans Strategic Partnering](#) (*The Wall Street Journal*)



## MEMBER NEWS

[The Blood Emergency Readiness Corps](#) (BERC) recently announced that it has grown in size to 19 participating community blood centers in 18 states. The coalition of blood centers are “commit[ted] to joining together to be prepared for mass transfusion disasters that might strike” by “collecting extra units on a rotating ‘on call’ schedule to ensure an emergency reserve of blood is available for emergency needs.” According to a news release, BERC “experienced its first activation responding to a mass shooting at a grocery store in Memphis, Tenn.” The seven founding members included:



- **Oklahoma Blood Institute** (Oklahoma City, O.K.);
- **Houchin Community Blood Bank** (Bakersfield, Calif.);
- **The Community Blood Center** (Appleton, Wisc.);
- **Central Pennsylvania Blood Bank** (Hummelstown, Penn.);
- **We Are Blood** (Austin, Texas);
- **South Texas Blood & Tissue Center** (San Antonio, Texas); and
- **Carter BloodCare** (Bedford, Texas)

The centers have now been joined by:

- **Coastal Bend Blood Center** (Corpus Christi, Texas);
- **LIFELINE Blood Services** (Jackson, Tenn.);
- **ImpactLife** (Davenport, Iowa);
- **The Blood Center** (New Orleans, L.A.);
- **MEDIC Regional Blood Center** (Knoxville, Tenn.);
- **Northern California Community Blood Bank** (Eureka, Calif.);
- **SunCoast Blood Centers** (Sarasota, Fla.);
- **Cascade Regional Blood Services** (Tacoma, Wash.);
- **Blood Assurance** (Chattanooga, Tenn.);
- **Western Kentucky Regional Blood Center** (Owensboro, K.Y.);
- **The Blood Connection** (Greenville, S.C.); and
- **LifeSouth Community Blood Centers** (Gainesville, Fla.).

“The addition of these new blood centers makes the reserve more robust and responsive,” said Nelson Hellwig, MBA, chief executive officer of the Alliance for Community Transfusion Services (ACTS), which coordinates BERC’s logistics and administration. “We’re thrilled to see so many new blood centers step up and commit to our emergency reserve program.”

(Source: BERC Announcement, 11/9/21)

A [column](#) appearing in *USA TODAY* raises awareness of the need for a diverse pool of blood donors. The reporter, Lindsey Leake of *Treasure Coast Newspapers*, documents her experience donating at **OneBlood** while calling attention to the need for more donors to prevent blood shortages, particularly black donors. “I

(continued on page 7)

MEMBER NEWS (continued from page 6)

recalled consenting to a transfusion if needed during surgery,” said Ms. Leake in the column. “I didn’t require one, but now realize I had expected an ample blood supply would be at my disposal. The people who had given a piece of themselves for my benefit never crossed my mind. I’m glad I could return the favor.”

(Source: USA TODAY, [Black blood donors are desperately needed, so I donated for the first time](#), 11/8/21)

**NEW on CollABOrate****COLLABORATE**

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

**Recent discussion topics on the ABC [CollABOrate](#) Online Member Community include:**

- [Post Donation Reaction Follow-up](#) (COLLECTIONS & DONOR SERVICES)
- [Experience with Training Development](#) (QUALITY BYTES)
- [Cryoprecipitate Production](#) (TECHNICAL DIRECTORS)

ABC members are encouraged to [login](#) and join the conversations today!

**We Welcome Your Letters**

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.





## GLOBAL NEWS

**Sanquin, national blood provider in the Netherlands, and PamGene International B.V. recently [announced](#) an extension to their research partnership.** As a part of the collaboration, the organizations are “working to enhance the development of PamGene’s IOpener® blood-based diagnostic test to predict immunotherapy response in cancer patients.” Annelies Turksma, head of Laboratory at Sanquin Immunomonitoring Services, stated in the news release, “At Sanquin, we have the flexibility and knowledge to provide a broad range of services that support research and development. In this way, together with the Dutch blood bank donors, we can contribute to PamGene’s mission to provide better solutions for patients.” Rik de Wijn, PamGene’s Head of Diagnostic Assay Services Laboratory added in the news release, “Sanquin provides services such as isolation of high-quality peripheral blood mononuclear cells from blood samples of cancer patients eligible for immunotherapy, which is a fundamental element of our ongoing clinical studies. Next to being the Dutch institute for blood products and services, Sanquin is an excellent research partner, and I am very pleased with the expansion of our collaboration. Combining both organization’s knowledge and experience in blood sampling and diagnostic development enables us to take significant steps towards further optimization of the IOpener diagnostic workflow.”

(Source: Sanquin [News Release](#), 11/11/21)

**The World Health Organization (WHO) issued a [news release](#) this week raising concern about progress towards measles elimination worldwide and decreasing surveillances.** According to the organization, “more than 22 million infants missed their first dose of measles vaccine - three million more than in 2019, marking the largest increase in two decades... Weak measles monitoring, testing and reporting for measles jeopardize countries’ ability to prevent outbreaks of this highly infectious disease. Major measles outbreaks occurred in 26 countries and accounted for 84 percent of all reported cases in 2020” Kevin Cain, MD, director of Global Immunization at the Centers for Disease Control and Prevention (CDC), added, “[w]e must act now to strengthen disease surveillance systems and close immunity gaps, before travel and trade return to pre-pandemic levels, to prevent-- deadly measles outbreaks and mitigate the risk of other vaccine-preventable diseases.” While measles is not believed to be transfusion-transmitted, a [fact sheet](#) published in October 2011 by AABB’s Transfusion Transmitted Diseases (TTD) Committee noted “the existence of cell associated viremia and the detection of viral RNA by RT-PCR raises a theoretical concern.”

(Source: WHO [News Release](#), 11/10/21)

**The Department of Health and Social Care and NHS England [announced](#) vaccine mandates this week for health and social care workers.** According to the announcement, “[h]ealth and social care providers in England will be required to ensure workers are fully vaccinated against COVID-19, unless they are exempt, under plans announced by the Health and Social Care Secretary... The regulations will apply to health and social care workers who have direct, face-to-face contact with people while providing care... unless they are exempt... The requirements will come into force in the spring, subject to the passage of the regulations through Parliament. There will be a 12-week grace period between the regulations being made and coming into force to allow those who have not yet been vaccinated to have both doses. Enforcement would begin from April 1<sup>st</sup>, subject to Parliamentary approval.”

(Source: Department of Health and Social Care [News Release](#), 11/9/21) ♦





## COMPANY NEWS

**BloodHub** has [received](#) 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its BloodRelay v1.1.0 blood establishment computer system (BECS). According to a recent announcement from the company, this marks BloodHub's second successful submission of a BECS to the agency. "BloodRelay's underlying architecture is an engineering achievement," said BloodHub Founder and Chief Operating Officer Andrew Pandelakis in a news release. "It allows each implementation to be customized to meet the needs of each lab's users while maintaining the tight process controls needed for a regulated application. Over time, we intend to improve BloodRelay to enhance the end user experience."

(Source: BloodHub [News Release](#), 10/15/21)

**Pfizer Inc.** and **BioNTech SE** [requested](#) that FDA authorize additional ("booster") dose of its COVID-19 vaccine in all adults. According to a report from *Reuters*, the companies presented data to the agency "showing that the booster shot would help prevent disease across all ages." The FDA previously authorized a booster dose to be administered to immunocompromised individuals in addition to:

- "individuals 65 years of age and older;
- individuals 18 through 64 years of age at high risk of severe COVID-19; and
- individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19."

(Source: *Reuters*, [Pfizer seeks FDA nod for COVID vaccine boosters for U.S. adults](#), 11/10/21)

**Editas Medicine, Inc.** recently [announced](#) that a phase I/II clinical trial of the company's gene editing therapy to treat sickle cell disease (SCD) has started enrolling patients. Dosing is expected to take place during the first half of 2022. According to the news release, "[Editas] uses a proprietary engineered CRISPR/Cas12a ribonucleoprotein (RNP) to edit the HBG1/2 promoter mimicking a benign and naturally occurring human fetal hemoglobin mutation. This site is a naturally validated location, as patients with Hereditary Persistence of Fetal Hemoglobin (HPFH) harbor the sickle cell mutation but do not exhibit symptoms of the disease. The Company believes that targeting this site is potentially a more effective approach with better long-term safety than editing the BCL11A enhancer."

(Source: Editas Medicine, Inc. [News Release](#), 11/8/21)

**Regeneron Pharmaceuticals, Inc.** [reported](#) "additional positive results from a Phase III trial jointly run with the National Institute of Allergy and Infectious Diseases (NIAID) which assessed use of a single dose of investigational REGEN-COV® to prevent COVID-19 in uninfected individuals. According to a company news release, the new analyses demonstrate, "EGEN-COV reduced the risk of contracting COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.6 percent during the pre-specified follow-up period (months 2-8)." Results previously [published](#) in the *New England Journal of Medicine* showed that "the trial met its primary endpoint, reducing the risk of COVID-19 (i.e., laboratory-confirmed symptomatic SARS-CoV-2 infections) by 81.4 percent within one month of receiving REGEN-COV (p<0.0001). The new results released today describe a pre-specified analysis for the following 7 months, throughout which an additional 45 symptomatic infections occurred. During this time period, REGEN-COV continued to prevent infection, without requiring additional doses."

(Source: Regeneron Pharmaceuticals, Inc. [News Release](#), 11/8/21) ◆



## CALENDAR

**Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

### 2021

Dec. 6-8. **American Association of Tissue Banks (AATB) Annual Meeting (Virtual)**. Registration is [open](#).

Dec. 1. **U.S. Department of Health and Human Services (HHS) Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) (Virtual)**. More information available soon.

### 2022

Mar. 7-9. **ABC Annual Meeting, Washington, D.C.** [Registration](#) is open. More information available [here](#).

May 10-12. **2022 ADRP Conference, Phoenix, Ariz.** Additional details coming [soon](#) and abstract [submission](#) is now open.

June 4-8. **37<sup>th</sup> Annual International Congress of ISBT, Kuala Lumpur, Malaysia.** Additional details coming [soon](#). ♦

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**Director of Quality Assurance and Compliance.** Located in the magnificent California coastal redwoods, The Northern California Community Blood Bank has a low-stress environment and vibrant community relationship. Come join our team! Drive cultural transformation and promote the recognition and reporting of errors and improvement in quality and safety. Our Blood Bank seeks a Director of Quality Assurance and Compliance to oversee the quality assurance (QA) program for all areas of the blood center and its operations. This individual ensures that all pertinent details of the collection, manufacture, and distribution of blood products are in compliance with regulatory and standard-setting agencies. The ideal candidate will have experience leading quality improvement programs and expertise with risk management and accrediting organizations, ideally in a blood bank, health care, or laboratory environment. This candidate will have familiarity with FDA submissions, biologic regulations, and current good manufacturing practices (cGMP). For details, please visit [www.nccbb.net/employment](http://www.nccbb.net/employment).

**Manager, Plasma Operations.** Blood Centers of America (BCA) is a national cooperative comprising over 50 blood center members. BCA is seeking an individual with industry experience to serve as Manager, Plasma Operations. This position is responsible for specific aspects of the Plasma for Fractionation Program including managing day-to-day inquiries and operational tasks for this

business unit. The person in this role must be successful in understanding the technical requirements of multiple agreements and assisting members with plasma optimization and contract compliance. The ideal candidate will possess outstanding communication abilities, relationship development talent and strong customer service skills; five to 10 years of progressive experience in blood banking or similar field is required. Proven track record in a managerial role is a plus. BCA is based near Providence, Rhode Island. Will consider remote location for the right candidate. Position requires up to 20% overnight travel. Submit resume to [careers@bca.coop](mailto:careers@bca.coop).

**Senior Geospatial Analyst.** Blood Centers of America (BCA) is a national cooperative comprising over 50 blood center members. BCA is seeking an individual with industry experience to serve as Senior Geospatial Analyst. This position is responsible for specific aspects of the Geospatial and Business Intelligence Programs, including managing the day-to-day inquiries and tasks for this business unit. The person in this role must be successful in understanding the technical requirements of member blood centers to assist with donor optimization, marketing implementation and business intelligence gathering. They must be able to identify and extract useful results from large amounts of geographical data. A strong understanding of geography with data management, data analytics, market research, spatial analytics

(continued on page 11)

**POSITIONS** (continued from page 10)

and mapping experience is preferred. Professional experience with Arc/GIS/ArcGIS Pro ESRI is required. BCA is based near Providence, Rhode Island. Position requires approximately 10-20 percent overnight travel. Submit resume to [careers@bca.coop](mailto:careers@bca.coop).

**Divisional Supervisor of Clinical Service (Charleston, SC Region).** The Divisional Supervisor of Donor Services at The Blood Connection, Inc. provides direct supervision for mobile staging and operational support staff. This position is responsible for collections staff scheduling and coordinating staff changes post release of schedule. The Divisional Supervisor participates in staff call duties, performs bus driver duties (if applicable), and donor collection duties when required. Other responsibilities include submitting weekly time records for staff and assisting with daily QC review. Essential Operational Functions: Ensures supply of non-warehouse forms/tags used on mobiles and fixed sites are adequate. Assists with departmental equipment validations. Ensures mobile and center staging pods are adequately stocked and made available to outgoing blood drives and/or fixed site centers in a timely fashion. Ensures equipment returning from inside set-up drives are properly stored, and if required, charged. Ensures all box trucks are clean, organized, have adequate supplies and equipment upon return and prior to every departure. Other duties as assigned or acquired. Minimum Qualifications: High School Diploma or GED. Valid Driver's License with no major infractions and dependable transportation. Experience in mobile and apheresis collections required. Ability to organize and prioritize workload and meet deadlines. Ability to establish and maintain effective working relationships with staff, management, and peers. Please click [here](#) to apply.

**QRA Supervisor (Req#: R219667).** Reporting to the Regulatory & Accreditation Compliance Director, the QRA Supervisor is responsible for carrying out day-to-day activities at the Stanford Blood Center Quality & Regulatory Affairs department by appropriate management of the QRA Specialist, ensure timely review of records and completion of QRA activities. Assume the responsibility SBC safety initiatives, disaster preparedness, and support continuity of operation across the organization. Responsibilities: Quality Assurance/Training/ GMP/GTP/GLP: Lead the department's quality activities, initiatives, and process improvement activities. Perform training on QRA core functions and activities, Good Manufacturing Practice/Good Tissue Practice/Good Laboratory Practice, and safety. Compliance: Ensure compliance to current regulations and accreditation requirements by federal, state, county, and accreditation agencies. Team Leadership: Manage the performance of direct reports. Set team objectives, priorities, and resources to align staff with Blood Center objectives. Responsible for interviewing, hiring, training,

coaching, performance management, and performance reviews of direct reports. Safety: Lead the safety, emergency, and disaster management. Quality Management System: Provide oversight on the appropriate use of the quality management tools in handling the various documents, records, and activities of the blood center. Qualifications: Bachelor's Degree Required. One to two years supervisory experience in a regulated or GMP (Good Manufacturing Practice) required. Click [here](#) to apply.

**Director, Donor Recruitment.** LifeStream, a local non-profit organization providing blood services for more than 80 hospitals in Southern California, is searching for a Director, Donor Recruitment to lead the Donor Recruitment Team. Reporting to the Vice President, Operations, and managing a staff of 16 employees, the Director of Donor Recruitment is responsible for developing and deploying cohesive recruitment strategies to increase annual collections through the acquisition of new blood donors, new donor groups, and increased frequency of current donors. Also responsible for aligning staffing resources at all Donor Centers and Mobile Blood Drives to ensure daily, monthly, and annual collection goals are efficiently achieved. This individual will monitor operational performance data to ensure effective and efficient use of staffing resources to achieve desired collection targets. This position works closely with multiple departments to ensure successful drives. The ideal candidate will possess a bachelor's degree (BA) in Business, Marketing, Public Relations, or related field. Or three to five years sales management experience, leading a successful sales/recruitment team. Strong management/sales experience required. Must have proven and significant growth record in territories and/or sales. Demonstrated experience in sales/territory management skills, strong leadership and team building skills, excellent verbal and written communication and public speaking skills required. Bilingual a plus. Apply online: [www.LStream.org](http://www.LStream.org). E-mail: [recruitment@LStream.org](mailto:recruitment@LStream.org). EOE.

**Clinical Laboratory Scientist - MT Certified.** LifeSouth Community Blood Centers is currently seeking Level III Clinical Laboratory Scientists in Stone Mountain, GA. This position is responsible for performing and interpreting clinical laboratory tests that require the exercise of independent judgment. Must be MT certified; confirmatory testing experience preferred. Applicants should apply here: <https://lifesouth.csod.com/ux/ats-careersite/5/home/requisition/2342?c=lifesouth>. ♦